New dual monoclonal ELISA for measuring plasma osteopontin as a biomarker associated with survival in prostate cancer: clinical validation and comparison of multiple ELISAs.
New dual monoclonal ELISA for measuring plasma osteopontin as a biomarker associated with survival in prostate cancer: clinical validation and comparison of multiple ELISAs.
P. H. Anborgh,Sylvia M. Wilson,8 Authors,A. Chambers
2009 · DOI: 10.1373/clinchem.2008.117465
Clinical Chemistry · 50 Citations
TLDR
The availability of a clinically validated, dual monoclonal-based ELISA will provide consistent reagents for studies of OPN plasma concentrations in cancer and other pathologies.